Shots:

• Ginkgo & WARF collaborated to discover GD2 CAR T-cell therapies with improved persistence, proliferation, fitness & other functional properties using Ginkgo's high-throughput combinatorial CAR discovery & screening platform to improve efficacy
• Ginkgo will be in charge of designing & characterizing novel intracellular signaling domains that prevent the exhaustion of T-cells in the context of GD2 solid tumors using its platform
• To advance the development of novel CAR discovery, both intend to work together on the development of a pooled in vivo screening platform. Ginkgo will use its capabilities & expertise in mammalian cell engineering to enable high throughput CAR T-cell screening for the identification & improvement of next-generation therapeutic candidates for its partners

Ref: PR Newswire | Image: Ginkgo